NCT05552976

Brief Summary

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
606

participants targeted

Target at P75+ for phase_3

Timeline
40mo left

Started Jan 2023

Longer than P75 for phase_3

Geographic Reach
26 countries

204 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Jan 2023Jul 2029

First Submitted

Initial submission to the registry

September 21, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 23, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

January 10, 2023

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 18, 2026

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 25, 2029

Last Updated

April 1, 2026

Status Verified

March 1, 2026

Enrollment Period

3.5 years

First QC Date

September 21, 2022

Last Update Submit

March 30, 2026

Conditions

Keywords

BMS-986348CC-92480CarfilzomibDexamethasoneMultiple MyelomaMezigdomide

Outcome Measures

Primary Outcomes (1)

  • Progression-free Survival (PFS)

    Up to approximately 5 years

Secondary Outcomes (15)

  • Recommended Mezigdomide Dose

    Up to 12 months

  • Plasma concentrations of Mezigdomide in Combination with Carfilzomib and Dexamethasone

    Up to 176 days

  • Overall Survival (OS)

    Up to approximately 5 years

  • Overall Response (OR)

    Up to approximately 5 years

  • Rate Of Very Good Partial Response (VGPR) Or Better (VGPRR)

    Up to approximately 5 years

  • +10 more secondary outcomes

Study Arms (2)

MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)

EXPERIMENTAL
Drug: MezigdomideDrug: CarfilzomibDrug: Dexamethasone

Kd (Carfilzomib + Dexamethasone)

ACTIVE COMPARATOR
Drug: CarfilzomibDrug: Dexamethasone

Interventions

Specified dose on specified days

Also known as: BMS-986348, CC-92480
MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)

Specified dose on specified days

Also known as: Kyprolis
Kd (Carfilzomib + Dexamethasone)MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)

Specified dose on specified days

Also known as: Decadron, Dex
Kd (Carfilzomib + Dexamethasone)MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.
  • i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
  • ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
  • iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels \> 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
  • Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, \[with or without\] hematopoietic stem cell transplant, (with or without) consolidation, and/or \[with or without\] maintenance therapy).
  • Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received \< 2 cycles are still eligible).
  • Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
  • Participant must have documented disease progression during or after their last antimyeloma regimen.

You may not qualify if:

  • Participant who has had prior treatment with mezigdomide or carfilzomib.
  • Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (207)

Local Institution - 0046

Mobile, Alabama, 36604, United States

Location

Local Institution - 0005

Cerritos, California, 90703, United States

Location

Local Institution - 0190

Irvine, California, 92618, United States

Location

Local Institution - 0187

Los Angeles, California, 90017, United States

Location

Local Institution - 0344

Santa Rosa, California, 95403, United States

Location

Local Institution - 0339

Stockton, California, 95204, United States

Location

Local Institution - 0279

Newark, Delaware, 19713, United States

Location

Local Institution - 0341

Fort Myers, Florida, 33901, United States

Location

Local Institution - 0342

St. Petersburg, Florida, 33705, United States

Location

Local Institution - 0340

West Palm Beach, Florida, 33401, United States

Location

Local Institution - 0348

Atlanta, Georgia, 30303, United States

Location

Local Institution - 0291

Atlanta, Georgia, 30322, United States

Location

Saint Alphonsus Regional Medical Center

Boise, Idaho, 83706, United States

Location

Local Institution - 0289

Annapolis, Maryland, 21401, United States

Location

Local Institution - 0204

Boston, Massachusetts, 02215, United States

Location

Local Institution - 0346

Minneapolis, Minnesota, 55404, United States

Location

Local Institution - 0222

Little Silver, New Jersey, 07739, United States

Location

Local Institution - 0199

The Bronx, New York, 10467, United States

Location

Local Institution - 0322

Cleveland, Ohio, 44106, United States

Location

Local Institution - 0172

Columbus, Ohio, 43214, United States

Location

Local Institution - 0321

Providence, Rhode Island, 02903, United States

Location

Local Institution - 0338

Greer, South Carolina, 29650, United States

Location

Local Institution - 0349

Chattanooga, Tennessee, 37404, United States

Location

Local Institution - 0323

Nashville, Tennessee, 37203, United States

Location

Local Institution - 0337

Fort Worth, Texas, 76104, United States

Location

Local Institution - 0328

Houston, Texas, 77025, United States

Location

Local Institution - 0044

Houston, Texas, 77030, United States

Location

Local Institution - 0195

Temple, Texas, 76508, United States

Location

Local Institution - 0345

Norfolk, Virginia, 23502, United States

Location

Local Institution - 0343

Roanoke, Virginia, 24014, United States

Location

Local Institution - 0006

Tacoma, Washington, 98405, United States

Location

Local Institution - 0347

Vancouver, Washington, 98684, United States

Location

Local Institution - 0243

Morgantown, West Virginia, 26506, United States

Location

Local Institution - 0336

Marshfield, Wisconsin, 54449, United States

Location

Local Institution - 0008

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina

Location

Local Institution - 0079

ABB, Buenos Aires F.D., C1199ABB, Argentina

Location

Local Institution - 0182

Rosario, Santa Fe Province, 2000, Argentina

Location

Local Institution - 0319

San Miguel de Tucumán, Tucumán Province, 4000, Argentina

Location

Local Institution - 0150

Buenos Aires, 1431, Argentina

Location

Local Institution - 0151

Córdoba, 5000, Argentina

Location

Local Institution - 0077

Camperdown, New South Wales, 2050, Australia

Location

Local Institution - 0160

Gosford, New South Wales, 2250, Australia

Location

Local Institution - 0263

Port Macquarie, New South Wales, 2444, Australia

Location

Local Institution - 0078

St Leonards, New South Wales, 2065, Australia

Location

Local Institution - 0026

Sydney, New South Wales, 2010, Australia

Location

Local Institution - 0024

Adelaide, South Australia, 5000, Australia

Location

Local Institution - 0131

Bendigo, Victoria, 3550, Australia

Location

Local Institution - 0224

East Melbourne, Victoria, 3002, Australia

Location

Local Institution - 0127

Heidelberg, Victoria, 3084, Australia

Location

Local Institution - 0025

Melbourne, Victoria, 3065, Australia

Location

Local Institution - 0266

Vienna, Vienna, 1060, Austria

Location

Local Institution - 0020

Linz, 4020, Austria

Location

Local Institution - 0017

Vienna, 1090, Austria

Location

Local Institution - 0121

Salvador, Estado de Bahia, 41253-190, Brazil

Location

Local Institution - 0076

Porto Alegre, Rio Grande do Sul, 90470-340, Brazil

Location

Local Institution - 0085

São Paulo, São Paulo, 01509-010, Brazil

Location

Local Institution - 0075

Rio de Janeiro, 20775-001, Brazil

Location

Local Institution - 0073

São Paulo, 04537-080, Brazil

Location

Local Institution - 0305

Plovdiv, 4002, Bulgaria

Location

Local Institution - 0309

Sofia, 1407, Bulgaria

Location

Local Institution - 0304

Sofia, 1431, Bulgaria

Location

Local Institution - 0183

Halifax, Nova Scotia, B3H 2Y9, Canada

Location

Local Institution - 0275

London, Ontario, N6A 5W9, Canada

Location

Local Institution - 0184

Toronto, Ontario, M5G 2M9, Canada

Location

Local Institution - 0318

Hefei, Anhui, 230031, China

Location

Local Institution - 0061

Beijing, Beijing Municipality, 100020, China

Location

Local Institution - 0057

Beijing, Beijing Municipality, 100043, China

Location

Local Institution - 0056

Beijing, Beijing Municipality, 100730, China

Location

Local Institution - 0123

Fuzhou, Fujian, 350000, China

Location

Local Institution - 0138

Guangzhou, Guangdong, 510000, China

Location

Local Institution - 0315

Guangzhou, Guangdong, 510515, China

Location

Local Institution - 0051

Zhengzhou, Henan, 450008, China

Location

Local Institution - 0066

Wuhan, Hubei, 430002, China

Location

Local Institution - 0054

Wuhan, Hubei, 430030, China

Location

Local Institution - 0071

Changsha, Hunan, 410013, China

Location

Local Institution - 0103

Changsha, Hunan, 410013, China

Location

Local Institution - 0180

Nanjing, Jiangsu, 210009, China

Location

Local Institution - 0111

Nantong, Jiangsu, 226001, China

Location

Local Institution - 0104

Suzhou, Jiangsu, 215006, China

Location

Local Institution - 0069

Wuxi, Jiangsu, 214023, China

Location

Local Institution - 0095

Nanchang, Jiangxi, 330006, China

Location

Local Institution - 0052

Changchun, Jilin, 130021, China

Location

Local Institution - 0096

Shenyang, Liaoning, 110001, China

Location

Local Institution - 0176

Shenyang, Liaoning, 110004, China

Location

Local Institution - 0060

Xi'an, Shaanxi, 710126, China

Location

Local Institution - 0072

Jinan, Shandong, 250012, China

Location

Local Institution - 0118

Shanghai, Shanghai Municipality, 200025, China

Location

Local Institution - 0317

Shanghai, Shanghai Municipality, 200080, China

Location

Local Institution - 0091

Tianjin, Tianjin Municipality, 300060, China

Location

Local Institution - 0058

Kunming, Yunnan, 650101, China

Location

Local Institution - 0050

Hangzhou, Zhejiang, 310003, China

Location

Local Institution - 0115

Wenzhou, Zhejiang, 32500, China

Location

Local Institution - 0059

Taiyuan, 030032, China

Location

Local Institution - 0153

Medellín, Antioquia, 05034, Colombia

Location

Local Institution - 0156

Valledupar, Cesar Department, 200001, Colombia

Location

Local Institution - 0154

Bogota, Cundinamarca, 111151, Colombia

Location

Local Institution - 0324

Piedecuesta, Santander Department, 681017, Colombia

Location

Local Institution - 0155

Cali, 760035, Colombia

Location

Local Institution - 0032

Aarhus, Central Jutland, 8200, Denmark

Location

Local Institution - 0065

Roskilde, Region Sjælland, 4000, Denmark

Location

Local Institution - 0129

Odense, Region Syddanmark, 5000, Denmark

Location

Local Institution - 0125

Vejle, 7100, Denmark

Location

Local Institution - 0124

Ulm, Baden-Wurttemberg, 89081, Germany

Location

Local Institution - 0330

Munich, Bavaria, 81241, Germany

Location

Local Institution - 0333

Hanover, Lower Saxony, 30161, Germany

Location

Local Institution - 0335

Dortmund, North Rhine-Westphalia, 44263, Germany

Location

Local Institution - 0029

Kiel, Schleswig-Holstein, 24105, Germany

Location

Local Institution - 0331

Jena, Thuringia, 07747, Germany

Location

Local Institution - 0007

Berlin, 12203, Germany

Location

Local Institution - 0102

Cologne, 50937, Germany

Location

Local Institution - 0329

Dresden, 01307, Germany

Location

Local Institution - 0334

Düsseldorf, 40479, Germany

Location

Local Institution - 0015

Heidelberg, D-69120, Germany

Location

Local Institution - 0030

Leipzig, 04103, Germany

Location

Local Institution - 0133

Nuremberg, 90419, Germany

Location

Local Institution - 0014

Würzburg, 97080, Germany

Location

Local Institution - 0136

Pátrai, Achaḯa, 26504, Greece

Location

Local Institution - 0135

Athens, Attikí, 11528, Greece

Location

Local Institution - 0134

Thessaloniki, Thessaloníki, 570 10, Greece

Location

Local Institution - 0178

Hksar, 0, Hong Kong

Location

Local Institution - 0036

Pécs, Baranya, 7624, Hungary

Location

Local Institution - 0043

Debrecen, Hajdú-Bihar, 4032, Hungary

Location

Local Institution - 0094

Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400, Hungary

Location

Local Institution - 0042

Budapest, 1088, Hungary

Location

Local Institution - 0019

Budapest, 1097, Hungary

Location

Local Institution - 0167

Gurgaon, Haryana, 122001, India

Location

Local Institution - 0161

Bengaluru, Karnataka, 560027, India

Location

Local Institution - 0168

Mumbai, Maharashtra, 400012, India

Location

Local Institution - 0171

Thane, Maharashtra, 400602, India

Location

Local Institution - 0170

New Delhi, National Capital Territory of Delhi, 110085, India

Location

Local Institution - 0261

Mohali, Punjab, 160055, India

Location

Local Institution - 0174

Chennai, Tamil Nadu, 600036, India

Location

Local Institution - 0165

Hyderabad, Telangana, 500033, India

Location

Local Institution - 0310

Hyderabad, Telangana, 500068, India

Location

Local Institution - 0164

Hyderabad, Telangana, 500084, India

Location

Local Institution - 0230

Chandigarh, 160012, India

Location

Local Institution - 0264

Holon, Central District, 5810001, Israel

Location

Local Institution - 0267

Ẕerifin, Central District, 70300, Israel

Location

Local Institution - 0277

Jerusalem, 9112001, Israel

Location

Local Institution - 0145

Meldola, Emilia-Romagna, 47014, Italy

Location

Local Institution - 0143

Milan, Lombardy, 20122, Italy

Location

Local Institution - 0142

Rozzano, Milano, 20089, Italy

Location

Local Institution - 0189

Bologna, 40138, Italy

Location

Local Institution - 0148

Catanzaro, 88100, Italy

Location

Local Institution - 0147

Lecce, 73100, Italy

Location

Local Institution - 0144

Pisa, 56100, Italy

Location

Local Institution - 0146

Udine, 33100, Italy

Location

Local Institution - 0269

Nagoya, Aichi-ken, 467-8602, Japan

Location

Local Institution - 0214

Kashiwa, Chiba, 277-8577, Japan

Location

Local Institution - 0210

Kitakyushu-shi, Fukuoka, 806-8501, Japan

Location

Local Institution - 0211

Sapporo, Hokkaido, 003-0804, Japan

Location

Local Institution - 0217

Higashiibaraki, Ibaraki, 3113117, Japan

Location

Local Institution - 0300

Kanazawa, Ishikawa-ken, 920-8641, Japan

Location

Local Institution - 0209

Shiwa-gun Yahaba-cho, Iwate, 028-3695, Japan

Location

Local Institution - 0234

Kamakura, Kanagawa, 247-8533, Japan

Location

Local Institution - 0225

Koshigaya, Saitama, 343-0845, Japan

Location

Local Institution - 0236

Itabashiku, Tokyo, 173-8610, Japan

Location

Local Institution - 0219

Koto-ku, Tokyo, 135-8550, Japan

Location

Local Institution - 0303

Chūō, Yamanashi, 409-3898, Japan

Location

Local Institution - 0215

Chiba, 260-8677, Japan

Location

Local Institution - 0226

Fukuoka, 810-8563, Japan

Location

Local Institution - 0235

Fukuoka, 815-8555, Japan

Location

Local Institution - 0220

Kumamoto, 860-8556, Japan

Location

Local Institution - 0216

Kyoto, 602-8566, Japan

Location

Local Institution - 0213

Nagasaki, 852-8104, Japan

Location

Local Institution - 0212

Okayama, 701-1192, Japan

Location

Local Institution - 0301

Osaka, 545-8586, Japan

Location

Local Institution - 0241

Tokyo, 105-8461, Japan

Location

Local Institution - 0218

Tokyo, 150-8935, Japan

Location

Local Institution - 0113

Breda, North Brabant, 4818 CK, Netherlands

Location

Local Institution - 0194

Enschede, 7512 KZ, Netherlands

Location

Local Institution - 0049

Bergen, Hordaland, 5021, Norway

Location

Local Institution - 0112

Stavanger, Rogaland, 4021, Norway

Location

Local Institution - 0081

Oslo, 0450, Norway

Location

Local Institution - 0316

San Juan, 00909, Puerto Rico

Location

Local Institution - 0282

Bucharest, București, 022328, Romania

Location

Local Institution - 0284

Brasov, 500052, Romania

Location

Local Institution - 0302

Bucharest, 022328, Romania

Location

Local Institution - 0287

Bucharest, 030171, Romania

Location

Local Institution - 0306

Sibiu, 557260, Romania

Location

Local Institution - 0158

Singapore, Central Singapore, 119074, Singapore

Location

Local Institution - 0159

Singapore, Central Singapore, 169608, Singapore

Location

Local Institution - 0238

Seoul, Seoul-teukbyeolsi [Seoul], 03080, South Korea

Location

Local Institution - 0239

Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea

Location

Local Institution - 0240

Seoul, Seoul-teukbyeolsi [Seoul], 06591, South Korea

Location

Local Institution - 0126

Badalona, Barcelona [Barcelona], 08916, Spain

Location

Local Institution - 0092

Barcelona, Barcelona [Barcelona], 08035, Spain

Location

Local Institution - 0038

L'Hospitalet Del Llobregat, Barcelona [Barcelona], 08908, Spain

Location

Local Institution - 0200

Madrid, Madrid, Comunidad de, 28009, Spain

Location

Local Institution - 0108

Majadahonda, Madrid, Comunidad de, 28222, Spain

Location

Local Institution - 0201

San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain

Location

Local Institution - 0037

Valencia, Valenciana, Comunitat, 46010, Spain

Location

Local Institution - 0107

Granada, 18012, Spain

Location

Local Institution - 0047

Madrid, 28015, Spain

Location

Local Institution - 0105

Málaga, 29010, Spain

Location

Local Institution - 0274

Chiayi City, Chiayi, 613, Taiwan

Location

Local Institution - 0177

Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan

Location

Local Institution - 0012

Kaohsiung City, 82445, Taiwan

Location

Local Institution - 0001

Taichung, 407, Taiwan

Location

Local Institution - 0002

Tainan, 704, Taiwan

Location

Local Institution - 0162

Taipei, 11217, Taiwan

Location

Local Institution - 0139

Plymouth, Devon, Pl6 8DH, United Kingdom

Location

Local Institution - 0067

Cringleford, England, NR4 7UY, United Kingdom

Location

Local Institution - 0196

Glasgow, Glasgow City, G12 0YN, United Kingdom

Location

Local Institution - 0273

Birmingham, B9 5SS, United Kingdom

Location

Local Institution - 0080

Leeds, LS9 7TF, United Kingdom

Location

Local Institution - 0040

Taunton, TA1 5DA, United Kingdom

Location

Related Links

MeSH Terms

Conditions

RecurrenceMultiple Myeloma

Interventions

carfilzomibDexamethasoneCalcium Dobesilate

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsNeoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedBenzenesulfonatesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsArylsulfonatesArylsulfonic AcidsSulfonic AcidsSulfur AcidsSulfur Compounds

Study Officials

  • Bristol-Myers Squibb

    Bristol-Myers Squibb

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Masking Details
This is an open-label study; however, any review of aggregate study data by the Sponsor will be performed in a blinded manner.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a two-stage inferentially seamless design.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 21, 2022

First Posted

September 23, 2022

Study Start

January 10, 2023

Primary Completion (Estimated)

July 18, 2026

Study Completion (Estimated)

July 25, 2029

Last Updated

April 1, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
See Plan Description
Access Criteria
See Plan Description
More information

Locations